[ TRANSACTION RECORD ]

JPMorgan Chase & Co. Investment in Cerevel Therapeutics Inc. — 2023

VERIFIED VECTOR ID: 002137 · tx-233
M SOURCE NODE — FUNDER
JPMorgan Chase & Co.
Finance United States
$8,700,000,000
EQUITY
06/12/2023
Q DESTINATION NODE — RECIPIENT
Cerevel Therapeutics Inc.
Company United States
Amount (USD)
$8.7B
Flow Type
EQUITY
Transaction Date
06/12/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity JPMorgan Chase & Co.
AUM 3900000
HQ Location United States
Sector Finance
Recipient Profile [ Q ]
Entity Cerevel Therapeutics Inc.
Entity Type Company
Jurisdiction United States
Intelligence Note

AbbVie Inc. agreed to acquire Cerevel Therapeutics for 8.7 billion dollars to expand its neuroscience drug pipeline with advanced treatments for Parkinson’s disease and mood disorders. This transaction integrates Cerevel’s deep neuroscience expertise into AbbVie’s global pharmaceutical platform. The deal represents a major institutional investment in complex brain disorders.

Σ
Primary Forensic Source https://news.abbvie.com/2023-12-06-AbbVie-to-Acquire-Cerevel-Therapeutics-in-Strategic-Step-to-Strengthen-Neuroscience-Pipeline/
✓ SOURCE LINKED